SCHEMBL4199169

SCHEMBL4199169

COc1ccc(NS(=O)(=O)c2cc(C)c(Cl)cc2C)c2c1C[C@@H](N(C)C)CC2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.66
QRFPR Q96P65 1/20 0.66
ALDH1A1 P00352 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
TP53 P04637 3/20 0.41
TSHR P16473 2/20 0.41
USP2 O75604 1/20 0.41
RAB9A P51151 1/20 0.41
MAPK1 P28482 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
POLB P06746 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4206759 0.86 HTR6 (0.60) HTR6QRFPRALDH1A1TP53MAPK1
SCHEMBL4209406 0.86 HTR6 (0.62) HTR6QRFPRALDH1A1NPSR1TP53
SCHEMBL4209386 0.85 HTR6 (0.79) HTR6QRFPRALDH1A1NPSR1TP53
SCHEMBL4209206 0.85 HTR6 (0.75) HTR6QRFPRALDH1A1TSHRCHRM2
SCHEMBL4205768 0.85 HTR6 (0.66) HTR6QRFPRALDH1A1NPSR1TP53
SCHEMBL4211815 0.85 HTR6 (0.78) HTR6QRFPRALDH1A1NPSR1TSHR
SCHEMBL4210930 0.85 HTR6 (0.63) HTR6QRFPRALDH1A1NPSR1TP53
SCHEMBL4209165 0.85 HTR6 (0.66) HTR6QRFPRALDH1A1NPSR1TP53
SCHEMBL4203602 0.85 HTR6 (0.60) HTR6QRFPRCHRM2CHRM1CHRM3
SCHEMBL4204288 0.85 HTR6 (0.63) HTR6QRFPRCHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor HTR6, HTR1A, HTR1D HTR6 1/4885QRFPR 81/4885ALDH1A1 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.